Lymphoma News

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

COVID-19 variants pose a greater threat to certain patients with cancer, particularly those with hematologic malignancies, confirming the need to promote vaccination within this population, according to data presented at ESMO Congress 2021.

The FDA granted accelerated approval to zanubrutinib for treatment of patients with relapsed or refractory marginal zone lymphoma who received at least one anti-CD-20-based regimen.

Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.

The FDA approved zanubrutinib for adults with Waldenström macroglobulinemia.

Age and ethnic background appeared associated with inadequate follow-up care among young adult childhood cancer survivors, according to study results published in JNCI Cancer Spectrum.

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.

Patients with newly diagnosed cancer were more likely to develop kidney failure than a group of controls without cancer who exhibited similar characteristics in terms of age, sex, eGFR and the presence of diabetes or hypertension.

Few scientific advances have generated the optimism and enthusiasm that surround CRISPR.

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma failed to meet its primary endpoint of improved EFS, according to the agent’s manufacturer.